Notice NOT-HL-23-112 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-163 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-113 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-24-007 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to enhance NCIs program for conducting early phase clinical trials in children with cancer, thereby facilitating the introduction of high priority novel agents into the pediatric oncology setting in a timely manner. This ability to quickly conduct first in children studies is critical to NCIs overall clinical research program for children with cancer. The primary scope of the Pediatric Early Phase Clinical Trials Network (PEP-CTN) is to design and conduct pediatric phase 1 trials that will often include phase 2 expansion cohorts. Conduct of the phase 2 study components within the PEP-CTN is efficient and allows intensive study monitoring for toxicity for these agents undergoing their initial evaluation in children. When phase 1 testing results for an agent are available, phase 2 studies will also be within the remit of the PEP-CTN. As well, the PEP-CTN will conduct pilot studies of novel regimens to determine their tolerability so that they can proceed to definitive testing in phase 3 clinical trials.

Notice NOT-GM-23-052 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-24-027 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) promotes collaborative research programs to support the development/enhancement of infrastructure (e.g., tools, surveys, biospecimens, data) for Alzheimer's disease (AD) and AD-related dementias (AD/ADRD) neuroscience research in low- and middle-income countries (LMICs) in Africa. Specifically, the National Institute on Aging (NIA) seeks to support Phase Innovation Awards Cooperative Agreement (UG3/UH3) projects to enable: (1) the formation of transformative collaborations between institutions/scientists in the US and LMICs in Africa; (2) the development, or enhancement of research infrastructure and resources for studies of AD/ADRD neuroscience relevant to Africaas well as to examine how social or behavioral factors influence AD/ADRD in Africa; (3) the initiation of pilot or exploratory studies that will inform future research for AD/ADRD neuroscience in Africa. These research infrastructure programs are expected to contribute to the long-term goals of building sustainable AD/ADRD neuroscience research capacity and research,ultimately leading to prevention and mitigation strategies for AD/ADRD in Africa. Income categories for LMICs in Africa are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.

Funding Opportunity RFA-RM-23-012 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications from eligible organizations that can serve as Health Equity Research Hubs (Hubs) for awarded community-led health equity structural intervention (CHESI) projects within the Community Partnerships to Advance Science for Society (ComPASS) Program. The Hubs will serve as a centralized research resource, providing tailored scientific, technical, and collaborative support for sustainable community engagement, research capacity building, and training to assigned CHESI projects that address SDOH and structural factors to improve health outcomes. The Hubs are one of three complementary initiatives under the ComPASS Program, which also include the CHESI projects and the ComPASS Coordination Center.

Funding Opportunity PAR-24-027 from the NIH Guide for Grants and Contracts. The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, serum, and genomic DNA) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page (https://doi.org/10.3886/Series606) at the University of Michigans National Addiction and HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Researchs (ICPSR) website.

Funding Opportunity PAR-23-280 from the NIH Guide for Grants and Contracts. The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Notice NOT-CA-23-085 from the NIH Guide for Grants and Contracts

Notice NOT-AA-23-018 from the NIH Guide for Grants and Contracts

Notice NOT-AT-24-012 from the NIH Guide for Grants and Contracts

Notice NOT-DA-23-037 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-279 from the NIH Guide for Grants and Contracts. The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.

Notice NOT-CA-23-087 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-274 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

Funding Opportunity RFA-AG-24-046 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) aims toprovide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies. Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.

Notice NOT-CA-23-081 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-23-290 from the NIH Guide for Grants and Contracts. The purpose of this funding announcement is to invite proposals focused on developing strategies and interventions to improve diagnostic safety in the heterogenous ambulatory care environment. AHRQ is interested in providing support designed to develop, test, and evaluate ambulatory care activities that will improve diagnostic safety and quality.

Notice NOT-DK-23-030 from the NIH Guide for Grants and Contracts